JP2012515722A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515722A5
JP2012515722A5 JP2011546446A JP2011546446A JP2012515722A5 JP 2012515722 A5 JP2012515722 A5 JP 2012515722A5 JP 2011546446 A JP2011546446 A JP 2011546446A JP 2011546446 A JP2011546446 A JP 2011546446A JP 2012515722 A5 JP2012515722 A5 JP 2012515722A5
Authority
JP
Japan
Prior art keywords
antigen
composition
subject
item
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/021547 external-priority patent/WO2010085509A1/en
Publication of JP2012515722A publication Critical patent/JP2012515722A/ja
Publication of JP2012515722A5 publication Critical patent/JP2012515722A5/ja
Pending legal-status Critical Current

Links

JP2011546446A 2009-01-20 2010-01-20 抗原特異的寛容の誘導のための組成物および方法 Pending JP2012515722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14594109P 2009-01-20 2009-01-20
US61/145,941 2009-01-20
PCT/US2010/021547 WO2010085509A1 (en) 2009-01-20 2010-01-20 Compositions and methods for induction of antigen-specific tolerance

Publications (2)

Publication Number Publication Date
JP2012515722A JP2012515722A (ja) 2012-07-12
JP2012515722A5 true JP2012515722A5 (enExample) 2013-05-16

Family

ID=42356186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546446A Pending JP2012515722A (ja) 2009-01-20 2010-01-20 抗原特異的寛容の誘導のための組成物および方法

Country Status (12)

Country Link
US (4) US20120076831A1 (enExample)
EP (1) EP2389193A4 (enExample)
JP (1) JP2012515722A (enExample)
KR (1) KR20110117684A (enExample)
CN (1) CN102325546A (enExample)
AU (1) AU2010206854A1 (enExample)
CA (1) CA2750098A1 (enExample)
IL (1) IL214163A0 (enExample)
MX (1) MX2011007559A (enExample)
SG (2) SG193843A1 (enExample)
TW (1) TW201039843A (enExample)
WO (1) WO2010085509A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2598120B1 (en) 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CN103429232B (zh) 2010-11-12 2016-03-16 盖茨咨询和项目管理公司 修饰的免疫调节粒子
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
EP2753362A4 (en) * 2011-09-08 2015-04-15 Univ Florida MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance
KR102283760B1 (ko) 2012-06-21 2021-08-03 노쓰웨스턴유니버시티 펩티드 접합된 입자
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
MX382466B (es) 2013-03-13 2025-03-13 Cour Pharmaceuticals Dev Company Partículas inmunomodificadoras para el tratamiento de la inflamación.
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
ES2834129T3 (es) 2013-06-04 2021-06-16 Selecta Biosciences Inc Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores
WO2014210540A1 (en) * 2013-06-28 2014-12-31 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
DK3033102T4 (da) 2013-08-13 2024-02-26 Univ Northwestern Peptidkonjugerede partikler
SG10201803780UA (en) 2013-11-04 2018-06-28 Uti Lp Methods and compositions for sustained immunotherapy
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (en) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
DK3256850T3 (da) 2015-02-09 2025-08-18 Slingshot Biosciences Inc Hydrogelpartikler med justerbare optiske egenskaber og fremgangsmåder til anvendelse deraf
ES3055030T3 (en) 2015-05-06 2026-02-09 Uti Lp Nanoparticle compositions for sustained therapy
JP7194593B2 (ja) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
EP3445332B1 (en) * 2016-04-18 2022-04-27 University of Maryland, College Park Harnessing quantum dots to study, visualize, and promote immune tolerance
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
JP7270946B2 (ja) * 2017-08-08 2023-05-11 国立大学法人浜松医科大学 自己免疫疾患の治療又は予防剤
EP3716949A4 (en) 2017-11-29 2022-05-18 UTI Limited Partnership METHODS OF TREATMENT OF AUTOIMMUNE DISEASES
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
AU2020316005A1 (en) * 2019-07-19 2022-02-24 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2022235125A1 (ko) * 2021-05-06 2022-11-10 서울대학교 산학협력단 항체 및 자가항원이 표면에 결합된 지질-생체고분자 나노입자 및 이의 용도
AU2023265684A1 (en) 2022-05-05 2024-11-21 Slingshot Biosciences, Inc. Engineered particles as red blood cell mimics and compositions containing same for hematology
CA3257621A1 (en) 2022-06-02 2023-12-07 Slingshot Biosciences, Inc. APOPTOTIC CELL MIMETIC
WO2024182722A1 (en) * 2023-03-01 2024-09-06 Georgia Tech Research Corporation Therapeutic nanoparticles for solid organ immune acceptance
CN117603417B (zh) * 2023-10-08 2026-06-23 吉林大学 一种球状聚合物纳米颗粒的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06157592A (ja) * 1992-11-24 1994-06-03 Hitachi Chem Co Ltd ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法
US5804201A (en) * 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5
AU2003216851B2 (en) * 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
WO2005046722A2 (en) * 2003-11-05 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20100028450A1 (en) * 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
JP5650406B2 (ja) * 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
US20080311140A1 (en) * 2007-05-29 2008-12-18 Baylor College Of Medicine Antigen specific immunosuppression by dendritic cell therapy
EP2057998A1 (en) * 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
EP2123261A1 (en) * 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
AU2009326818A1 (en) * 2008-12-11 2011-07-07 The Govenors Of The University Of Alberta Methods and systems for inducing immunologic tolerance to non-self antigens
WO2013184976A2 (en) * 2012-06-06 2013-12-12 Northwestern University Compositions and methods for antigen-specific tolerance

Similar Documents

Publication Publication Date Title
JP7586863B2 (ja) 共有ポリマー抗原コンジュゲート化粒子
US12533403B2 (en) Peptide conjugated particles
US11826407B2 (en) Peptide conjugated particles
JP2015522569A5 (enExample)
JP2014514331A5 (enExample)
JP2018111687A5 (enExample)
JP2014514332A5 (enExample)
HK40058733B (en) Peptide conjugated particles
HK40058733A (zh) 肽缀合颗粒
HK1225279A1 (en) Peptide conjugated particles
HK1225279B (en) Peptide conjugated particles
HK1209039B (en) Peptide conjugated particles